Federal Circuit rules in Amgen v Sandoz on remand from SCOTUS
14 December 2017
|
Michael Loney, New York
The Federal Circuit has ruled that Sandoz did not forfeit its preemption defence and the BPCIA preempts state law remedies in its biosimilars dispute with Amgen. The decision makes clear that brand biologic companies have no remedies available against a biosimilar applicant who is refusing to engage in the patent dance
The Federal Circuit has ruled that Sandoz did not forfeit its preemption defense and the BPCIA preempts state law remedies in its biosimilars dispute with Amgen, in an opinion on remand from the Supreme Court.
The Supreme Court’s June 12 decision...
Please
log in to read the rest of this article.
New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Already registered?
Please make sure you log in to read the rest of the article.
Log in
Join us now
Gain FREE access to up to five free articles when you register now. Join here